恐慌症治疗市场分析及预测（至2035年）：依类型、产品类型、服务、技术、应用、最终使用者、模式及阶段划分

预计到2034年，恐慌症治疗市场规模将从2024年的31亿美元成长至137亿美元，复合年增长率约为15.2%。恐慌症治疗市场涵盖旨在缓解恐慌症症状的治疗方法和药物，例如认知行为疗法、抗忧郁症和苯二氮平类药物。该市场的成长主要受心理健康意识的提高和焦虑症盛行率的上升所驱动。创新重点在于个人化治疗方案和数位疗法，同时，远端医疗解决方案也日益受到重视，以提高治疗的可及性和有效性。随着社会对恐慌症的歧视逐渐消除以及医疗技术的不断进步，该领域有望持续增长。

由于人们对焦虑症的认识不断提高，以及焦虑症盛行率的上升，恐慌症治疗市场预计将迎来强劲成长。药物是该市场的主导部分，其中选择性血清素再回收抑制剂（SSRIs）因其高效性而成为最大的细分市场。苯二氮平类药物紧追在后，能够快速缓解急性恐慌症状。心理疗法，尤其是认知行为疗法（CBT），是表现第二好的细分市场，并作为长期治疗策略日益受到重视。新兴的数位治疗方法，包括行动应用程式和远距治疗平台，正逐渐普及，以满足人们对便利治疗方案的需求。将虚拟实境（VR）技术融入治疗过程是一种创新趋势，它透过身临其境型体验来缓解症状。正念和瑜珈等辅助和替代疗法也越来越被人们接受，并有助于改善整体健康。市场正在加大对研发的投资，专注于个人化医疗方法，旨在优化治疗效果并提高患者的生活品质。

恐慌症治疗市场的特点是治疗方案多样化，包括药物和认知疗法。市场占有率主要由大型製药企业主导，其定价策略与品牌声誉和疗效密切相关。近期推出的新产品专注于创新给药方式和新型化合物，以提高患者依从性和治疗效果。药物基因组学和数位健康技术的进步正在推动治疗方案转向个人化。恐慌症治疗市场的竞争异常激烈，主要企业透过策略性併购主导。基准研究显示，市场呈现专业化和细分市场化的趋势。法规结构，尤其是在北美和欧洲，十分严格，影响市场动态和产品核可。资料隐私法规对数位治疗解决方案产生影响，需要製定强而有力的合规策略。儘管面临监管合规挑战和竞争压力，但受意识提升和技术创新的推动，该市场仍呈现出成长势头。

主要趋势和驱动因素：

受心理健康意识提升和焦虑症发病率上升的推动，恐慌症治疗市场正经历强劲成长。关键趋势包括治疗模式（例如数位疗法和远端医疗）的技术进步，这些进步提高了患者的就医便利性。人工智慧与诊断工具的融合进一步实现了治疗的个人化，并满足了日益增长的个人化医疗保健解决方案需求。製药业的创新也正在推动市场扩张，新型药物配方和非侵入性疗法正获得广泛认可。正念疗法和认知行为疗法等替代疗法的日益普及，促进了整体治疗方法的转变。监管支持和消除心理健康问题污名化的努力也是关键驱动因素，为市场成长创造了有利环境。此外，新兴经济体心理健康基础设施的快速发展也带来了市场机会。能够提供经济高效且扩充性的治疗方案的公司，将占据有利地位，在这个快速成长的市场中获利。随着人们对心理健康治疗的认识和接受度不断提高，恐慌症治疗市场预计将持续成长，尤其是在那些将心理健康视为整体健康关键组成部分的地区。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

• 宏观经济分析
• 市场趋势
• 市场驱动因素
• 市场机会
• 市场限制
• 复合年均成长率：成长分析
• 影响分析
• 新兴市场
• 技术蓝图
• 战略框架

第四章 细分市场分析

• 市场规模及预测：依类型
  • 药物治疗
  • 认知行为疗法
  • 正念疗法
  • 暴露疗法
  • 接纳与承诺疗法
  • 心理动力疗法
  • 支持性护理
• 市场规模及预测：依产品划分
  • 选择性血清素再回收抑制剂（SSRIs）
  • SNRIs（血清素-正肾上腺素再回收抑制剂）
  • 苯二氮平类药物
  • β阻断剂
  • 抗忧郁症
  • 治疗应用程式
  • 穿戴式装置
• 市场规模及预测：依服务划分
  • 住院治疗
  • 门诊治疗
  • 远距治疗
  • 团体治疗
  • 个别治疗
  • 紧急服务
• 市场规模及预测：依技术划分
  • 行动医疗技术
  • 远端医疗平台
  • 基于人工智慧的诊断
  • 虚拟实境疗法
• 市场规模及预测：依应用领域划分
  • 应对急性恐慌发作
  • 长期焦虑管理
  • 预防復发
• 市场规模及预测：依最终用户划分
  • 医院
  • 精神健康诊所
  • 居家医疗环境
  • 学术和研究机构
• 市场规模及预测：依实施方法划分
  • 处方笺治疗
  • 非处方药
  • 数位平台
• 市场规模及预测：依疾病阶段划分
  • 初步诊断
  • 开始治疗
  • 维持治疗
  • 后续

第五章 区域分析

• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 其他拉丁美洲地区
• 亚太地区
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲
  • 台湾
  • 亚太其他地区
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 义大利
  • 其他欧洲地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非
  • 撒哈拉以南非洲
  • 其他中东和非洲地区

第六章 市场策略

• 需求与供给差距分析
• 贸易和物流限制
• 价格、成本和利润率趋势
• 市场渗透率
• 消费者分析
• 法规概述

第七章 竞争讯息

• 市场定位
• 市场占有率
• 竞争基准
• 主要企业的策略

第八章 公司简介

• Mind Med
• Alkermes
• Sage Therapeutics
• Axsome Therapeutics
• Intra-Cellular Therapies
• Vista Gen Therapeutics
• Relmada Therapeutics
• Biohaven Pharmaceuticals
• Cerevel Therapeutics
• Karuna Therapeutics
• Minerva Neurosciences
• Otsuka Pharmaceutical
• Jazz Pharmaceuticals
• H. Lundbeck
• Neurocrine Biosciences
• ACADIA Pharmaceuticals
• Sunovion Pharmaceuticals
• Eisai
• Vanda Pharmaceuticals
• Supernus Pharmaceuticals

第九章：关于我们

Panic Attack Treatment Market is anticipated to expand from $3.1 billion in 2024 to $13.7 billion by 2034, growing at a CAGR of approximately 15.2%. The Panic Attack Treatment Market encompasses therapies and medications aimed at alleviating symptoms of panic disorders, including cognitive-behavioral therapy, antidepressants, and benzodiazepines. This market is driven by rising mental health awareness and increasing prevalence of anxiety disorders. Innovations focus on personalized treatment plans and digital therapeutics, with a growing emphasis on telehealth solutions to enhance accessibility and efficacy. The sector is poised for growth as societal destigmatization and healthcare advancements continue to evolve.

The Panic Attack Treatment Market is poised for robust growth, driven by increasing awareness and the rising prevalence of anxiety disorders. The pharmaceutical segment leads, with selective serotonin reuptake inhibitors (SSRIs) being the top-performing sub-segment due to their efficacy. Benzodiazepines follow closely, providing rapid relief for acute panic symptoms. Psychotherapy, particularly cognitive-behavioral therapy (CBT), is the second highest performing segment, gaining traction as a long-term treatment strategy. Emerging digital therapeutics, including mobile applications and teletherapy platforms, are gaining popularity, catering to the demand for accessible and convenient treatment options. The integration of virtual reality in therapy sessions is an innovative trend, offering immersive experiences to alleviate symptoms. Complementary and alternative therapies, such as mindfulness and yoga, are also gaining acceptance, enhancing overall well-being. The market is witnessing increased investment in research and development, focusing on personalized medicine approaches to optimize treatment outcomes and improve patient quality of life.

The Panic Attack Treatment Market is characterized by a diverse range of therapeutic options, including medications and cognitive therapies. Market share is primarily held by pharmaceutical giants, with pricing strategies aligning closely with brand reputation and efficacy. Recent product launches focus on innovative delivery methods and novel compounds, enhancing patient compliance and therapeutic outcomes. The market is witnessing a shift towards personalized treatment plans, driven by advancements in pharmacogenomics and digital health technologies. Competition within the Panic Attack Treatment Market is intense, with key players vying for dominance through strategic mergers and acquisitions. Benchmarking reveals a trend towards specialization and niche targeting. Regulatory frameworks, particularly in North America and Europe, are stringent, shaping market dynamics and influencing product approvals. Data privacy regulations impact digital therapy solutions, necessitating robust compliance strategies. The market is poised for growth, supported by increasing mental health awareness and technological innovations, despite challenges in regulatory compliance and competitive pressures.

Geographical Overview:

The Panic Attack Treatment Market is witnessing notable growth across diverse regions, each showcasing unique opportunities. North America leads the charge, driven by heightened awareness of mental health and substantial healthcare funding. The region's advanced healthcare infrastructure and increasing prevalence of anxiety disorders further bolster market expansion. Europe follows closely, with significant investments in mental health care and supportive government policies fostering a conducive environment for growth. The emphasis on innovative treatment approaches and research initiatives enhances the market's potential. In the Asia Pacific, the market is expanding rapidly, propelled by rising awareness and acceptance of mental health issues. Emerging economies like India and China are experiencing increased demand for effective treatment options, presenting lucrative opportunities for market players. Latin America and the Middle East & Africa are emerging growth pockets. These regions are recognizing the importance of mental health treatment, with increasing investments in healthcare infrastructure and awareness campaigns driving market growth.

The Panic Attack Treatment Market is influenced by global tariffs, geopolitical risks, and evolving supply chain dynamics. In Japan and South Korea, increasing tariffs and trade tensions with major economies are prompting investments in local pharmaceutical innovations and generic drug production. China's strategy focuses on bolstering domestic healthcare capabilities to mitigate the impact of international trade barriers. Taiwan, while a crucial player in pharmaceutical manufacturing, remains vulnerable to geopolitical tensions, particularly between the US and China. The global parent market for mental health treatment is expanding as awareness and diagnosis rates improve. By 2035, the market's growth will hinge on strategic regional partnerships and supply chain resilience. Middle East conflicts exacerbate global energy price volatility, indirectly affecting production and distribution costs in the healthcare sector.

Key Trends and Drivers:

The Panic Attack Treatment Market is experiencing robust growth, propelled by rising mental health awareness and increasing prevalence of anxiety disorders. Key trends include technological advancements in treatment methods, such as digital therapeutics and telemedicine, which are enhancing patient access and convenience. The integration of artificial intelligence in diagnostic tools is further refining treatment personalization, aligning with the growing demand for tailored healthcare solutions. Pharmaceutical innovations are driving market expansion, with novel drug formulations and non-invasive therapies gaining traction. The increasing acceptance of alternative therapies, like mindfulness and cognitive-behavioral therapy, underscores a shift towards holistic treatment approaches. Regulatory support and initiatives to destigmatize mental health issues are also pivotal drivers, fostering a more conducive environment for market growth. Moreover, the market is witnessing opportunities in emerging economies where mental health infrastructure is developing rapidly. Companies that can provide cost-effective and scalable treatment solutions are well-positioned to capitalize on these burgeoning markets. As awareness and acceptance of mental health treatment grow, the Panic Attack Treatment Market is poised for sustained expansion, particularly in regions prioritizing mental health as a critical component of overall well-being.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Mode
• 2.8 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Pharmacological Treatments
  • 4.1.2 Cognitive Behavioral Therapy
  • 4.1.3 Mindfulness-Based Therapy
  • 4.1.4 Exposure Therapy
  • 4.1.5 Acceptance and Commitment Therapy
  • 4.1.6 Psychodynamic Therapy
  • 4.1.7 Supportive Therapy
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 SSRIs
  • 4.2.2 SNRIs
  • 4.2.3 Benzodiazepines
  • 4.2.4 Beta-Blockers
  • 4.2.5 Antidepressants
  • 4.2.6 Therapeutic Apps
  • 4.2.7 Wearables
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 In-patient Treatment
  • 4.3.2 Out-patient Treatment
  • 4.3.3 Teletherapy
  • 4.3.4 Group Therapy
  • 4.3.5 Individual Therapy
  • 4.3.6 Emergency Services
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Mobile Health Technology
  • 4.4.2 Telemedicine Platforms
  • 4.4.3 AI-based Diagnostics
  • 4.4.4 Virtual Reality Therapy
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Acute Panic Attack Management
  • 4.5.2 Long-term Anxiety Management
  • 4.5.3 Relapse Prevention
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Hospitals
  • 4.6.2 Mental Health Clinics
  • 4.6.3 Homecare Settings
  • 4.6.4 Academic & Research Institutes
• 4.7 Market Size & Forecast by Mode (2020-2035)
  • 4.7.1 Prescription-based
  • 4.7.2 Over-the-counter
  • 4.7.3 Digital Platforms
• 4.8 Market Size & Forecast by Stage (2020-2035)
  • 4.8.1 Initial Diagnosis
  • 4.8.2 Treatment Initiation
  • 4.8.3 Maintenance
  • 4.8.4 Follow-up

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Mode
    • 5.2.1.8 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Mode
    • 5.2.2.8 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Mode
    • 5.2.3.8 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Mode
    • 5.3.1.8 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Mode
    • 5.3.2.8 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Mode
    • 5.3.3.8 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Mode
    • 5.4.1.8 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Mode
    • 5.4.2.8 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Mode
    • 5.4.3.8 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Mode
    • 5.4.4.8 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Mode
    • 5.4.5.8 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Mode
    • 5.4.6.8 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Mode
    • 5.4.7.8 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Mode
    • 5.5.1.8 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Mode
    • 5.5.2.8 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Mode
    • 5.5.3.8 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Mode
    • 5.5.4.8 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Mode
    • 5.5.5.8 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Mode
    • 5.5.6.8 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Mode
    • 5.6.1.8 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Mode
    • 5.6.2.8 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Mode
    • 5.6.3.8 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Mode
    • 5.6.4.8 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Mode
    • 5.6.5.8 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Mind Med
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Alkermes
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Sage Therapeutics
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Axsome Therapeutics
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Intra- Cellular Therapies
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Vista Gen Therapeutics
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Relmada Therapeutics
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Biohaven Pharmaceuticals
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Cerevel Therapeutics
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Karuna Therapeutics
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Minerva Neurosciences
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Otsuka Pharmaceutical
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Jazz Pharmaceuticals
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 H. Lundbeck
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Neurocrine Biosciences
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 ACADIA Pharmaceuticals
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Sunovion Pharmaceuticals
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Eisai
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Vanda Pharmaceuticals
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Supernus Pharmaceuticals
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us